Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Three scientific abstracts highlighting clinical research of terlipressin treatment for adults with HRS involving rapid reduction in kidney function1 will be presented at the ASN Scientific Meeting, reinforcing Mallinckrodt's ongoing commitment to critically ill patients – DUBLIN , Nov. 1, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that three scientific abstracts on clinical research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting in Orlando, Florida, from November 3-6. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization.2  Please see Limitation of Use and Important Safety Information, including Boxed Warning, below.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting

Mallinckrodt plc (NYSE:MNK ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller & Chief IR Officer Sigurdur Olafsson - President & CEO Bryan Reasons - Chief Financial Officer Conference Call Participants Gregory Fraser - Truist Securities David Amsellem - Piper Sandler Operator Good morning, and welcome to the Mallinckrodt Q2 2022 Earnings Announcement and Business Update Conference Call. All participants will be in listen-only mode.

Mallinckrodt plc (MNK) CEO Sigurdur Olafsson on Q2 2022 Results - Earnings Call Transcript

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patients hospitalized with hepatorenal syndrome (HRS) and acute kidney injury (AKI). The descriptive...

Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipressin in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) conducted in 26 hospitals...

Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® (nitric oxide)...

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1). HRS-1 is an acute and life-threatening syndrome...

Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin

ROCKFORD, Ill.--(BUSINESS WIRE)--In April 2017, Rockford sued Mallinckrodt and Express Scripts for antitrust violations. Rockford's lawsuit seeks to return more than $10 billion...

City of Rockford $10 Billion Lawsuit Against Pharmaceutical Giant Mallinckrodt Threatened by Bankruptcy

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company' s voluntary Chapter 11 petitions filed on...

Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations

Mallinckrodt Becomes The Third Major Opioid Producer To File For Bankruptcy

Shares of Mallinckrodt Plc tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged role in the U.S. opioid crisis. The drug maker said it aims to reduce total debt by $1.3 billion and to resolve opioid-related claims, as well as a False Claims Act lawsuit, Medicaid rebate lawsuit, and other legal matters.

Mallinckrodt's stock drops as it announces bankruptcy filing

Mallinckrodt Pharmaceuticals, facing billions of dollars in legal costs over its role in the nation's opiod crisis, filed for bankruptcy early Monday.

Opioid maker Mallinckrodt files for bankruptcy

Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations and pare down debt. Mallinckrodt becomes the third major opioid maker to seek bankruptcy protection to offload liabilities related to the U.S. opioid epidemic, reports Bloomberg.

Mallinckrodt Files For Chapter 11 Bankruptcy To Offload Opioid Fines

Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying higher rebates to state Medicaid programs for its top-selling drug.

Mallinckrodt files for bankruptcy amid U.S. opioid litigation

DUBLIN, Oct. 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware to modify its capital structure, including restructuring...

Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring

Amgen

Novartis

A House committee has issued detailed reports about some of their drug price increases.

Congressional Committee Accuses Amgen and Peers of Hiking Drug Prices to Meet "Aggressive" Revenue Targets

Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.

Mallinckrodt: A Series Of Unfortunate Events

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

Why Is Mallinckrodt (MNK) Down 3.9% Since Last Earnings Report?

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

Teva Pharmaceutical

The proposed law now goes to Gov. Gavin Newsom for his signature.

California Assembly Passes Generic-Drug Cost-Reduction Bill

ST. LOUIS, Aug. 24, 2020 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been recognized as a Manufacturing Leadership Award winner for outstanding achievement by the National.

Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards

Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma

STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

News for Mallinckrodt PLC Stock (MNK)